MLLT1 and acute myeloid leukemia: The growth of AML cells harboring oncogenic MLLrearrangements relies on the YEATS domain-containing protein ENL.Many small molecule inhibitors targeting ENL have been developed.To prioritize these inhibitors for in vivo studies, a NanoBRET systemwas introduced to evaluate their cellular permeability and potency.This screening identified inhibitor 13 as a promisingcandidate.